Bifidobacterium animalis subsp. lactis Bi-07

Bifidobacterium animalis subsp. lactis Bi-07 is a clinically studied probiotic strain that produces short-chain fatty acids, particularly acetate and lactate, which strengthen intestinal barrier function. This strain enhances digestive health by increasing beneficial bacterial populations and modulating immune responses through interaction with intestinal epithelial cells.

Origin & History

Bifidobacterium animalis subsp. lactis Bi-07 is a probiotic strain derived from the gut microbiota of healthy individuals. It is known for its resilience and ability to thrive in the digestive tract.

Historical & Cultural Context

This strain has been isolated from healthy human microbiota and has been used in various probiotic formulations.

Health Benefits

- Supports digestive health by promoting regular bowel movements, reducing constipation by 40%. This ensures a smoother digestive process. - Enhances immune system function by boosting the production of protective antibodies, reducing the incidence of infections. - May reduce inflammation by modulating immune responses, leading to decreased chronic inflammation markers. - Improves gut barrier function, preventing the entry of harmful pathogens and toxins. - Aids in nutrient absorption by maintaining a healthy gut lining, ensuring efficient uptake of vitamins and minerals. - Supports mental health by influencing the gut-brain axis, potentially reducing symptoms of depression. - Promotes cardiovascular health by lowering cholesterol levels, contributing to a healthier heart.

How It Works

Bi-07 adheres to intestinal epithelial cells via specific adhesins, producing acetate and lactate that lower colonic pH and inhibit pathogenic bacteria growth. The strain stimulates dendritic cells and enhances secretory IgA production through toll-like receptor signaling pathways. It strengthens tight junction proteins like claudin-1 and occludin, improving intestinal barrier integrity.

Scientific Research

Research supports its role in improving digestive health and boosting immunity, though further studies are needed to confirm other health claims.

Clinical Summary

Human clinical trials with sample sizes ranging from 60-200 participants demonstrate Bi-07's efficacy in reducing constipation by 40% and decreasing upper respiratory tract infections by 27%. Double-blind, placebo-controlled studies show significant improvements in stool frequency and consistency within 2-4 weeks at doses of 1-10 billion CFU daily. Evidence quality is moderate with most studies lasting 4-12 weeks, though longer-term safety data remains limited.

Nutritional Profile

- Rich in probiotics. - Supports gut health and immunity. - Enhances nutrient absorption.

Preparation & Dosage

Typical dosage ranges from 1 to 10 billion CFU per day. Consult a healthcare provider before use.

Synergy & Pairings

Lactobacillus plantarum Lp-115, Bifidobacterium longum SP 07/3, Streptococcus thermophilus TH-4

Safety & Interactions

Bi-07 is generally well-tolerated with mild gastrointestinal symptoms like bloating or gas occurring in less than 5% of users during the first week. No significant drug interactions have been reported, though immunocompromised individuals should consult healthcare providers before use. Safety during pregnancy and breastfeeding has not been established in clinical trials. Individuals with severe acute pancreatitis or compromised intestinal barrier function should avoid probiotic supplementation.